Ongoing media coverage continues to recognize and highlight the achievements of InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a preclinical biopharmaceutical company focused on developing therapies through research and development into the pharmacology of cannabinoids and drug delivery systems. The company was featured as a “Cannabis Runner” by Insider Financial earlier this year, and Forbes also more recently released an article calling InMed “more than just another cannabis drug company.”
“Although the company’s pipeline is expected to generate a significant amount of attention in 2018, InMed Pharmaceuticals’ manufacturing system and database are catching the eye of investors and biotech companies. THC and CBD have, of course, been used for treating medical conditions, but there are now more than 90 different cannabinoids identified in one plant, and all of these are thought to serve various purposes. InMed has managed to plug these different cannabinoids into its system, allowing the bioinformatics compounds to test them against various illnesses and drug compounds, matching the right cannabinoids to help fight specific diseases.”
“This tool has helped the company identify two therapies, one for epidermolysis bullosa (EB), a rare skin disease found in children, and one for glaucoma, a degenerative condition that causes damage to a person’s optic nerve. In addition to all of the above, the company has now developed a method of biosynthesis similar to that used to create synthetic insulin, but for cannabinoids. This process is not only cheaper, but quicker, and it gives access to cannabinoids that are not currently profitable to turn into drugs.”
To view the full article, visit http://nnw.fm/u2Xjk
About InMed Pharmaceuticals, Inc.
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
About HempNewsBreaks
HempNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of HempWire (HW). NNB keeps you up-to-date on active US Public Companies complementary to HW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
Please see full disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, CO
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
